Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
Join us later for a some very exciting pieces of translational science across a AIRDs.
All these abstracts sharing one thing in common: tissue, tissue, tissue!
16:30-18:00 Room A8.2
@RheumNow #EULAR2024 https://t.co/HrHP5tmHDD
Peter Nash drpnash
3 months 2 weeks ago
Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew
Topic: can observational study debunk RCT?
This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
The great debate on JAKi risk and special warnings
And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew
Get the popcorn ready 🍿
#EULAR2024 https://t.co/z50Ob8q0i0
Peter Nash drpnash
3 months 2 weeks ago
almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024
Peter Nash drpnash
3 months 2 weeks ago
« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024
TheDaoIndex KDAO2011
3 months 2 weeks ago
Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
🌎 Global disparities in steroid prescribing in #SLE
💊 HCQ assoc with decreased steroid use
📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics
📍SLE poster tour 15:30 TODAY
#EULAR2024
Abs #POS0013
@RheumNow https://t.co/7pL8kpeqOs
Peter Nash drpnash
3 months 2 weeks ago
LBA0001 (2024)
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
- looking good, nice results @rheumnow #EULAR2024
Peter Nash drpnash
3 months 2 weeks ago
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024
Peter Nash drpnash
3 months 2 weeks ago
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024
Peter Nash drpnash
3 months 2 weeks ago
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
And were are on folks!! 🎙️
Delighted to join @RheumNow faculty again this year
I will be covering RA and PsA topics during #EULAR2024
Don’t miss our Daily recaps live 6pm
Oh and if you see me around, come and say Hi! https://t.co/TrQ9b3WeSy
Peter Nash drpnash
3 months 2 weeks ago
Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab. Despite this, some patients remain refractory to these effective therapies.
